Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2020

View Archived Issues

Metacrine reports phase I data on FXR agonist MET-642

Interim analysis update on remestemcel-L study in COVID-19 ARDS

Phase II study of BN-Brachyury in chordoma shows signs of clinical activity

Olinvacimab plus pembrolizumab shows clinical benefit in phase Ib study in mTNBC

DZD-4205 demonstrates efficacy in phase I/II JACKPOT8 study in PTCL

Discovery of new PDIA1 inhibitor with antitumor activity in models of multiple myeloma

Chiesi Farmaceutici divulges new P2X3 receptor antagonists

Sage Therapeutics synthesizes CYP46A1 inhibitors

Kallyope identifies new FFAR1 agonists

Korea Pharma describes JAK1 inhibitors

University of California, Oakland patents modified ZIVK-based products for cancer

Preliminary phase I/II data for ZN-c5 monotherapy in ER-positive/HER2-negative breast cancer

Triumeq shown to slow down progression of MND in mice

Tumors, metastases activate mTOR in different ways

Soricimed to explore utility of SOR-C13 for COVID-19

FDA approves Orgovyx for advanced prostate cancer

FDA issues EUA for Moderna's mRNA-1273 for COVID-19

Phase III studies of faricimab in DME meet primary endpoint

FDA issues complete response letter for inclisiran

Qu Biologics to evaluate potential of QBKPN to prevent and treat SARS-CoV-2 infection

XEN-496 shows comparable PK data to that of retigabine

Nanoform announces first human dosing with nanoformed drug

European Commission approves Palforzia to treat peanut allergy

LACEWING study of Xospata in FLT3mut+ AML does not meet primary endpoint

FDA approves Xpovio for multiple myeloma after at least one prior therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...